CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the company and collaborating investigators from the Howard Hughes Medical Institute and Oregon Health & Science University Cancer Institute will present new data from preclinical studies on AP24534, a multi-targeted kinase inhibitor, at the 50th Annual Meeting of the American Society of Hematology (ASH) being held in San Francisco, California, December 6-9, 2008. The data to be presented relate to the potential utility of AP24534 in hematological malignancies, specifically chronic myeloid leukemia (CML) and acute myeloid leukemia (AML).
